
Zymeworks Inc (ZYME) Stock Forecast & Price Target
Zymeworks Inc (ZYME) Analyst Ratings
Bulls say
Zymeworks is a promising company with a positive outlook due to its strong drug development engine, deep preclinical pipeline in oncology and other therapeutic areas, and clinical candidate zanidatamab showing promising results in multiple Phase 1, Phase 2, and pivotal trials. With upcoming value inflection points, including potential FDA approval for Ziihera-based combinations and a second interim analysis for the combination of Ziihera, Tevimbra, and chemotherapy, there is potential for significant growth in the company's revenue and earnings in the future. However, there are risks associated with clinical trial failures and financing, and investors should monitor these factors closely.
Bears say
Zymeworks is a clinical-stage biopharmaceutical company with a negative outlook due to several factors. These include a reliance on a single product, YUPELRI, and potential commercial and regulatory risks associated with it. Additionally, the company faces the possibility of delays or setbacks in the development of its other pipeline products, which may impact its ability to generate revenue in the future. Moreover, there is a potential for dilution risk and partnership risks, along with uncertainties surrounding the success of its clinical trials and market uptake of its products.
This aggregate rating is based on analysts' research of Zymeworks Inc and is not a guaranteed prediction by Public.com or investment advice.
Zymeworks Inc (ZYME) Analyst Forecast & Price Prediction
Start investing in Zymeworks Inc (ZYME)
Order type
Buy in
Order amount
Est. shares
0 shares